Ember Therapeutics Inc
Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport'… Read more
Ember Therapeutics Inc (EMBT) - Total Liabilities
Latest total liabilities as of September 2015: $254.80K USD
Based on the latest financial reports, Ember Therapeutics Inc (EMBT) has total liabilities worth $254.80K USD as of September 2015.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ember Therapeutics Inc - Total Liabilities Trend (2012–2014)
This chart illustrates how Ember Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ember Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Ember Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Strattner Financial Group Corp
PINK:SCNG
|
USA | $44.01K |
|
Shengkai Innovations Inc
PINK:VALV
|
USA | $3.03 Million |
|
New Oriental Energy
PINK:NOEC
|
USA | $51.39 Million |
|
GeckoSystems International Corp
PINK:GOSY
|
USA | $318.33K |
|
Meltronix Inc
PINK:MTNX
|
USA | $17.39 Million |
|
Associates First Capital Corp
PINK:ASFZ
|
USA | $40.63 Billion |
|
Bourque Indts Inc
PINK:BORK
|
USA | $1.75 Million |
Liability Composition Analysis (2012–2014)
This chart breaks down Ember Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 110.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ember Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ember Therapeutics Inc (2012–2014)
The table below shows the annual total liabilities of Ember Therapeutics Inc from 2012 to 2014.
| Year | Total Liabilities | Change |
|---|---|---|
| 2014-12-31 | $238.65K | +10.24% |
| 2013-12-31 | $216.48K | +7.57% |
| 2012-12-31 | $201.24K | -- |